J9000 Insurance Policy Changes

HCPCS J9000 is officially defined as "Injection, doxorubicin hydrochloride, 10 mg." HCPCS J9000 is referenced in 9 tracked payer policy changes from Highmark and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J9000 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

High impact
Prior Authorization Changes to Oncology-related Codes
Highmark·Effective May 1, 2026
Effective May 1, 2026, Highmark is adding 115 oncology-related codes to their prior authorization requirement list, including common chemotherapy medications and radiation therapy procedures. All authorization requests for these codes must be submitted electronically through Availity Essentials and will be reviewed by Evolent as part of Highmark's oncology value-based care strategy.
High impact
Sacituzumab Govitecan-hziy (Trodelvy) (CPB 0971, reviewed 2026-04-24)
Aetna·Effective Apr 24, 2026
Aetna has updated its clinical policy for Sacituzumab Govitecan-hziy (Trodelvy, CPB 0971), effective April 24, 2026. The policy establishes coverage criteria for HER2-negative breast cancer, urothelial carcinoma (bladder, urethra, upper GU tract, and prostate), and requires mandatory precertification for all uses. Billing teams must implement precertification workflows and ensure claims comply with specific treatment line and prior therapy requirements.
High impact
Ixabepilone (Ixempra) (CPB 0869, reviewed 2026-04-07)
Aetna·Effective Apr 7, 2026
Aetna updated its coverage policy for Ixabepilone (Ixempra) effective April 7, 2026, establishing specific medical necessity criteria for breast cancer treatment. The policy covers ixabepilone as monotherapy for HER2-negative disease, as fourth-line combination therapy with trastuzumab for HER2-positive disease, and in combination with capecitabine for anthracycline/taxane-resistant disease with specific liver function requirements. All other indications, including triple-negative breast cancer and multiple other cancer types, are designated as experimental/investigational and not covered.
High impact
Loncastuximab Tesirine-lpyl (Zynlonta) (CPB 0994, reviewed 2026-09-15)
Aetna·Identified Oct 3, 2026
Aetna has updated its clinical policy for Loncastuximab Tesirine-lpyl (Zynlonta) effective immediately, establishing coverage criteria for four specific B-cell lymphoma indications: large B-cell lymphoma (after 2+ prior lines of therapy), histologic transformation of indolent lymphomas (after anthracycline treatment), HIV-related B-cell lymphomas (after 2+ prior lines), and post-transplant lymphoproliferative disorders (after 2+ prior lines). All uses require precertification before administration.
High impact
Polatuzumab Vedotin-piiq (Polivy) (CPB 0955, reviewed 2026-09-17)
Aetna·Identified Sep 30, 2026
Aetna has established updated coverage criteria for Polatuzumab Vedotin-piiq (Polivy) for treatment of multiple B-cell lymphoma subtypes, including DLBCL, high-grade B-cell lymphomas, and post-transplant lymphoproliferative disorders. All uses require mandatory precertification before administration. Coverage is limited to up to 6 cycles total, with specific combinations and clinical scenarios defined for initial and continuation therapy.
Medium impact
Hematopoietic Cell Transplantation for Selected Childhood Solid Tumors (CPB 0496, reviewed 2026-08-06)
Aetna·Effective Aug 6, 2026
Aetna updated its clinical policy on hematopoietic cell transplantation (HCT) for childhood solid tumors, effective immediately. The policy covers autologous HCT for high-risk neuroblastoma, relapsed/refractory disease in multiple tumor types (Ewing's sarcoma, PNET, ependymoma, retinoblastoma, Wilms' tumor), and establishes specific criteria for tandem vs. single transplants based on risk stratification. Allogeneic HCT and adoptive cellular immunotherapy remain experimental/unproven for all indications.
Medium impact
Trabectedin (Yondelis) (CPB 0903, reviewed 2026-01-13)
Aetna·Effective Jan 13, 2026
Aetna has updated its clinical policy for Trabectedin (Yondelis) effective January 13, 2026, establishing coverage criteria for specific sarcoma types including uterine leiomyosarcoma, soft tissue sarcoma, retroperitoneal/intra-abdominal sarcoma, pleomorphic rhabdomyosarcoma, solitary fibrous tumor, dedifferentiated liposarcoma, and epithelioid hemangioendothelioma. All other indications remain experimental/investigational. Billing teams must verify diagnosis codes and treatment lines align with approved criteria before claim submission.
Medium impact
Loncastuximab Tesirine-lpyl (Zynlonta) (CPB 0994, reviewed 2025-12-09)
Aetna·Effective Dec 9, 2025
Aetna has updated its clinical policy for Loncastuximab Tesirine-lpyl (Zynlonta) effective immediately, establishing coverage criteria for four B-cell lymphoma indications: relapsed/refractory large B-cell lymphoma, histologic transformation of indolent lymphomas, HIV-related B-cell lymphomas, and post-transplant lymphoproliferative disorders. All prescriptions require precertification before administration, and billing must use HCPCS code J9359 with appropriate chemotherapy administration codes.
Medium impact
Mogamulizumab-kpkc (Poteligeo) (CPB 0940, reviewed 2026-04-28)
Aetna·Identified Aug 16, 2026
Aetna has issued a fresh medical policy (CPB 0940, reviewed 2026-04-28) establishing coverage criteria for mogamulizumab-kpkc (Poteligeo) intravenous infusion for treating Adult T-cell leukemia/lymphoma (ATLL) and cutaneous T-cell lymphomas (mycosis fungoides and Sézary syndrome). This policy defines specific approved indications, dosing schedules (1 mg/kg IV infusion), and continuation-of-therapy criteria, with all other indications classified as experimental/investigational. Billing teams must implement coverage validation and prior authorization procedures for HCPCS code J9204 when claims are submitted.

Related

All billing codes J3590 C9399 J3490 99213 99214 99212

Get alerts for changes like this

Save a search and receive a daily digest whenever a new policy change matches your filters.

Create a free alert